论文部分内容阅读
目的探究吉非替尼对肺癌患者Ki-67及p53表达及预后影响。方法选取2007年10月~2014年6月浙江省肿瘤医院病理科收治的肺癌患91例,46例口服吉非替尼治疗的归入治疗组,45例采用紫杉醇联合顺铂化疗方案治疗的归入对照组。2组患者予以常规治疗以及个体化对症治疗后,均有支气管镜活检、粗针穿刺、胸水细胞包埋或手术样本,进行免疫组化染色后对比分析2组Ki-67及p53阳性表达率、p U值及复发率。结果与对照组相比,治疗组患者的Ki-67及p53阳性表达率较低(P<0.05),阴性表达率较高(P<0.05),Ki-67及p53p U值较低(P<0.05),复发率较低(P<0.05)。结论吉非替尼对肺癌患者Ki-67及p53的基因表达具有调控作用,抑制癌细胞的侵润和转移,改善临床疗效与预后。
Objective To investigate the effects of gefitinib on expression of Ki-67 and p53 and prognosis of lung cancer patients. Methods A total of 91 patients with lung cancer admitted to the Department of Pathology, Zhejiang Cancer Hospital from October 2007 to June 2014 were enrolled. 46 patients were treated with oral gefitinib and 45 patients were treated with chemotherapy combined with paclitaxel and cisplatin. Into the control group. After routine treatment and individualized symptomatic treatment in both groups, there were bronchoscopic biopsy, coarse needle puncture, pleural effusion or surgical specimens. After immunohistochemical staining, the positive expression rates of Ki-67 and p53 in the two groups were compared. p U value and recurrence rate. Results Compared with the control group, the expression rate of Ki-67 and p53 in the treatment group was lower (P<0.05), the negative rate was higher (P<0.05), and the Ki-67 and p53p U were lower (P< 0.05), the recurrence rate was lower (P<0.05). Conclusion Gefitinib can regulate the expression of Ki-67 and p53 in lung cancer patients, inhibit the invasion and metastasis of cancer cells, and improve clinical efficacy and prognosis.